Introduction {#s1}
============

The imbalance between the molecular mechanisms that govern oxidative stress, inflammation, immunity, and cell death are important causes of acute kidney injury (AKI) and chronic kidney diseases (CKD) ([@B67]). Both AKI and CKD can lead to diminished kidney function and are associated with high mortality and morbidity. Accumulated evidence demonstrated that natural products are alternative sources for treating renal diseases on account of the conventional experience and multi-target characteristics ([@B11]).

Artemisinin (ARS) is an effective constituent with a molecular weight of 282 originally extracted from traditional Chinese medicine *Artemisia annua L*, which was first discovered by Chinese scientists in 1972. Its chemical structure-sesquiterpene lactone with a peroxide bridge has been demonstrated to exert an excellent antimalarial effect ([@B75]; [@B9]). In the presence of heme or free iron, the production of reactive oxygen species and carbon-centered free radicals generated by the cleavage of the endoperoxide bridge can directly poison the parasites ([@B69]). ARS selectively kills plasmodium-infected red blood cells without destroying healthy cells, making it the recommended drug for the treatment of malaria ([@B34]) and more clinically effective than other antimalarial drugs such as hydroxychloroquine (HCQ) and chloroquine (CQ) ([@B21]; [@B15]). ARS has a rapid onset of action and can be rapidly absorbed by the gastrointestinal tract after oral administration, with half-live ranging from 2 to 5 h. It is mainly distributed in the liver, kidney, and bile, and approximately 80% of the drug was excreted through the urine and feces within 24 h of administration ([@B19]; [@B39]). Currently, a series of ARS derivatives (ARSs) with improved pharmacological features are used in clinical treatment including artemether (ARM), artesunate (ART), β-aminoarteether maleate (SM934), and dihydroartemisinin (DHA) (chemical structures were shown in [**Figure 1**](#f1){ref-type="fig"}). The half-lives of ARM (2--4 h), ART (\< 1 h), DHA (∼1 h) are shorter ([@B33]; [@B19]) and oral intake represents a relatively safe route in the clinic.

![Chemical structures of artemisinin and its derivatives.](fphar-11-00380-g001){#f1}

In addition to decades of remarkable progress against malaria, studies have demonstrated a variety of other pharmacological effects beyond antimalarial, such as anti-virus, anti-neoplastic, anti-inflammation as well as immunosuppressive effects ([@B3]). The properties of ARSs have been intensively reviewed in systemic lupus erythematosus, rheumatoid, arthritis, multiple sclerosis, etc ([@B65]; [@B55]), while the treatment of kidney disease has not been summarized. This review will focus on the proposed therapeutic properties and mechanisms of ARSs in kidney disease, and discuss the potential application of ARSs as novel agents for future treatment.

Search Strategy {#s2}
===============

Comprehensive literature searches for candidate studies were undertaken in two English and three Chinese biomedical databases from inception through February 2020. These databases included PubMed, Springer, Chinese National Knowledge Infrastructure, WanFang Med Online, and Chinese Biomedical Databases. Searches were limited to studies in English and Chinese. The following terms were used in the search: "artemisinin," "artemisinins," "artesunate," "dihydroartemisinin," "artemether," "SM934," "β-aminoarteether maleate," "kidney," "renal," "nephro," "nephritis," nephropathy."

Overview of Researches on ARSs in Renal Disease {#s3}
===============================================

The effects of ARSs were mainly studied on animal models and cells, with two clinical studies targeting lupus nephritis (LN). In a randomized, 5-year follow-up clinical trial for LN ([@B45]), the treatment group (ARS 0.6 g/d and cordyceps 3--4 g/d) was reported to improve 24 h urine protein, creatinine clearance rate, level of C3, and was more effective than the control group (tripterygium wilfordii polyglycosides tablets 1 mg/kg, three times a day and/or baoshenkang tablets 150 mg, three times a day). A 2-month randomized trial had similar findings ([@B36]), treatment with ART (50 mg, twice a day) was reported to improve systemic symptoms and reduce the immunological activity index than either before treatment or the control group with tripterygium wilfordii polyglycosides tablets (10 mg, three times a day and/or prednisone 0.5 mg/kg/d). However, these two studies were not blinded and placebo-controlled, which may result in information bias, and observations of larger samples are still lacking.

[**Table 1**](#T1){ref-type="table"} summarized the characteristics of animal studies with ARSs treatment, covering LN, adriamycin nephropathy (AN), subtotal nephrectomy (SNx), IgA nephropathy (IgAN), diabetic nephropathy (DN), AKI, unilateral ureteral obstruction (UUO), pristine or lipopolysaccharide (LPS)-induced nephritis, nephrotic syndrome (NS), and Heymann nephritis (HN). *In vitro* cell models and *in vivo* animal models investigations for ARSs efficacy on kidney disease involve various aspects including oxidative stress, inflammation action, and immune response, we will describe the effects of ARSs in sections below.

###### 

Study characteristics of animal experiments in kidney disease.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Animal model     Drug and dose                                                                                              Application mode             Targets                                                                                                                                                                        Reference
  ---------------- ---------------------------------------------------------------------------------------------------------- ---------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------
  LN mice          ARS (150 mg/kg/d)                                                                                          p.o. for 8 weeks             ↓TNF-α, ↓IL-6 in serum; ↓NF-kB, ↓NF-kB p65, ↓TGF-β1 in renal tissue                                                                                                            [@B76]

  LN mice          ARS (150 mg/kg/d) + prednisone (3.225 mg/kg/d)                                                             p.o. for 8 weeks             ↑GRα, ↓GRβ in PBMC; ↑P300/CBP in renal tissue                                                                                                                                  [@B79]

  LN mice          ARS (5.55 mg/kg/d) + HCQ (16.6 mg/kg/d)                                                                    p.o. for 8 weeks             ↓Anti-dsDNA, ↓ANA, ↓IgG, ↓IFN-γ, ↓TNF-α, ↑TGF-β1 in serum; ↑KLF15, ↓NF-κB in renal tissue                                                                                      [@B40]

  LN mice          ART (125 mg/kg/d)                                                                                          p.o. for 16 weeks            ↓Anti dsDNA, ↓ANA, ↓MCP-1 in serum; ↓VEGF in renal tissue                                                                                                                      [@B29]; [@B30];

  LN mice          ART (50 mg/kg/d)                                                                                           p.o. for 16 weeks            ↓ICAM-1 in renal tissue                                                                                                                                                        [@B72];

  LN mice          SM934 (10 mg/kg/d)                                                                                         p.o. for 4 weeks             ↓IL-2, ↓IL-17, ↓IFN-γ, ↓Anti-dsDNA IgG in serum; ↓STAT-1, ↓STAT 3, ↓STAT5, ↓CD3+B220+CD4-CD8- T cells, ↓Th1, ↓Th17, ↑Treg in splenocytes                                       [@B26]

  LN mice          SM934 (2.5, 5, 10 mg/kg/d)                                                                                 p.o. for 8 weeks             ↓IL-6, ↓IL-10, ↓IL-17, ↓IL-21 in serum;\                                                                                                                                       [@B22]
                                                                                                                                                           ↑B cell, ↑germinal center B cells, ↓activated B cells, ↓plasma cells in splenocytes; ↓Blimp-1, ↑BCL-6, ↓TLR7/9 in renal tissue                                                 

  LN mice          DHA (5, 25, 125 mg/kg/d)                                                                                   p.o. for 10 d                ↓NF-κB, ↓NF-κB p65 in renal tissue                                                                                                                                             [@B14]

  LN mice          DHA (5, 25, 125 mg/kg/d)                                                                                   p.o. for 10 d                ↓TNF-α in serum; ↓NF-κB, ↓NF-κB p65, ↑IκB-α in renal tissue                                                                                                                    [@B35]

  LN mice          DHA (60 mg/kg/d); DHA (60 mg/kg/d) +\                                                                      p.o. for 8 weeks             ↓Fractalkine, ↓NF-κB, ↓NF-κB p65 in renal tissue                                                                                                                               [@B84]
                   Prednisolone (9 mg/kg/d)                                                                                                                                                                                                                                                                                               

  LN mice          DHA (25, 50, 100 mg/kg/d)                                                                                  p.o. for 12 weeks            ↑SIGIR, ↓TLR4/NF-κB in renal tissue                                                                                                                                            [@B27]

  AKI mice         DHA (20, 40, 80 mg/kg)                                                                                     p.o. for 10 d (pretreated)   ↓MDA, ↑GSH, ↑SOD activity in renal tissue                                                                                                                                      [@B4]

  AKI mice         DHA (50 mg/kg/d)                                                                                           p.o. for 1 d                 ↑Occludin, ↓TNF-α in renal tissue                                                                                                                                              [@B12]

  AKI mice         DHA (20 mg/kg/d)                                                                                           p.o. for 3 d (pretreated)    ↓Apaf-1, ↓cleaved-caspase-3, ↓IL-1β, ↓IL-5, ↓IL-6, ↓IL-17A, ↓IFN-γ, ↓TNF-α, ↓CXCL1, ↓MCP-1, ↓MIP-2 in serum; ↓NF-κBp65, ↓MDA, ↓NO, ↑GSH, ↑CAT, ↑SOD activity in renal tissue   [@B44]

  DN rats          ARS (300 mg/kg/d)                                                                                          i.p. for 3, 6 weeks          ↓PDGF-B, ↓TIMP-2, ↑MMP-2, ↓PKC activation in renal tissue                                                                                                                      [@B86]; [@B87]; [@B88]

  DN rats          ARS (300 mg/kg/d)                                                                                          i.p. for 4 weeks             ↓DNA binding activity of NF−κB, ↓c-fos, ↓c-jun, ↓DNA binding activity of AP-1 in renal tissue                                                                                  [@B92]; [@B93]; [@B94]

  DN rats          ARS (300 mg/kg/d)                                                                                          p.o. for 4 weeks             Differentially gene expression profile                                                                                                                                         [@B82]

  DN rats          ART (10, 30 mg/kg/d)                                                                                       p.o. for 12 weeks            ↓TLR4, ↓IL-8 in renal tissue                                                                                                                                                   [@B56]

  DN rats          ARM (670 mg/kg/d)                                                                                          p.o. for 12 weeks            ↓H~2~O~2~, ↑PGC-1α in serum and urine; ↑mitochondrial MPC content in renal tissue                                                                                              [@B24]

  IgAN rats        ARS (16.7 mg/kg/d) + HCQ (16.7 mg/kg/d);\                                                                  p.o. for 90 d                ↓Deposition of IgA immune complexes and C3 in renal tissue                                                                                                                     [@B41]
                   ARS (8.3 mg/kg/d) + HCQ (25 mg/kg/d)                                                                                                                                                                                                                                                                                   

  IgAN rats        ARS (33.33 mg/kg/d); HCQ (33.33 mg/kg/d); AH (16.65 mg/kg/d, 33.33 mg/kg/d, 66.66 mg/kg/d, ARS: HCQ=1:3)   p.o. for 4 weeks             ↓IL-4, ↓IL-17, ↑IFN-γ, ↓Th2, ↓Th17, ↑Th1, ↑Treg proportion in peripheral blood and spleen; ↓deposition of IgA immune complexes and C3 in renal tissue                          [@B5]

  IgAN rats        ART (25, 50 mg/kg/d)                                                                                       p.o. for 4 weeks             ↓MCP-1 in renal tissue                                                                                                                                                         [@B53]

  IgAN rats        ART (25, 50 mg/kg/d)                                                                                       p.o. for 4 weeks             ↓IL-2, ↓IL-6 in serum                                                                                                                                                          [@B49]

  UUO mice         ART (25, 50 mg/kg/d)                                                                                       p.o. for 3, 7, 14, 21 d      ↓α-SMA, ↓CTGF in renal tissue                                                                                                                                                  [@B52]

  UUO mice         ART (25, 50 mg/kg/d)                                                                                       p.o. for 3, 7 d              ↓NF-κB p65, ↑IkB-α, ↑Smad7 in renal tissue                                                                                                                                     [@B50]

  UUO mice         ART (15, 30, 60 mg/kg/d)                                                                                   p.o. for 14 d                ↓Fibronectin, ↓collagen I, ↓α-SMA, ↑E-cadherin, ↓USAG-1, ↑BMP-7 in renal tissue                                                                                                [@B8]

  UUO mice         DHA (40 mg/kg/d)                                                                                           p.o. for 14 d                ↓Collagen I, ↓collagen III, ↓Fibronectin,\                                                                                                                                     [@B91]
                                                                                                                                                           ↓TGF-β1, ↓PCNA, ↓α-SMA, ↓P13k/AKT in renal tissue                                                                                                                              

  NS rats          ART (5 mg/kg/d)                                                                                            i.p. for 28 d                ↓Triglyceride, ↑albumin in serum; ↓polymorphonuclear and mononuclear cells infiltration in renal tissue                                                                        [@B58]

  Nephritis mice   DHA (20 mg/kg/d)                                                                                           i.p. for 48 h                ↓TNF-α, ↓IL-6 in serum                                                                                                                                                         [@B78]

  Nephritis mice   ART (28.8 mg/kg/d)                                                                                         p.o. for 6 weeks             ↓TNF-α, ↓IL-6 in serum; ↓α-SMA, ↓TLR4, ↓MyD88, ↓NF-κB p65, ↓TGF-β1, ↓caspase-3 in renal tissue                                                                                 [@B71]

  AN rats          ARS (150 mg/kg/d)                                                                                          p.o. for 4 weeks             ↑Nephrin, ↑podocin in renal tissue                                                                                                                                             [@B80]

  HN rats          ARS (100 mg/kg/d)                                                                                          p.o. for 4 weeks             ↑Podocyte, ↑nephrin, ↑podocin in urine                                                                                                                                         [@B42]

  HN rats          SM934 (12.5, 25 mg/kg/d)                                                                                   p.o. for 28 d                ↑Podocin, ↑nephrin, ↑desmin, ↓TGF-β1, ↓Smad2/3 phosphorylation, ↑Smad7, ↓EMT in renal tissue                                                                                   [@B37]

  SNx rats         ARS (100 mg/kg/d)                                                                                          p.o. for 16 weeks            ↓TGF‐β1, ↓FSP1, ↓CTGF, ↓NLRP3 activation, ↓ASC, ↓NF‐κB signaling pathway in renal tissue                                                                                       [@B74]
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LN, lupus nephritis; AN, adriamycin nephropathy; SNx, subtotal nephrectomy; IgAN, IgA nephropathy; DN, diabetic nephropathy; AKI, acute kidney injury; UUO, unilateral ureteral obstruction; NS, nephrotic syndrome; HN, Heymann nephritis; ARS, artemisinin; DHA, dihydroartemisinin; ART, artesunate; ARM, artemether; HCQ, hydroxychloroquine; AH, artemisinin combined with hydroxychloroquine; TNF-α, tumor necrosis factor alpha; BAFF, B cell activating factor; GRα, glucocorticoid receptors alpha; GRβ, glucocorticoid receptors beta; IFN-γ, interferon-gamma; IκB-α, nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor alpha; Apaf-1, apoptotic protease activating factor-1; CXCL1, chemokine (C-X-C motif) ligand 1; IL-1β, interleukin-1 beta; IL-2, interleukin-2; IL-6, interleukin-6; IL-5, interleukin-5; IL-17A, interleukin-17A; KLF15, Krüppel-like factor 15; MCP-1, monocyte chemoattractant protein 1; MyD88, myeloid differentiation primary response 88; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NF-κB p65, nuclear factor-κB protein 65; P300, EP300 or E1A binding protein p300; CBP, CREB binding protein, STAT-1,-3,-5, signal transducer and activator of transcription-1,-3,-5, TGF-β1, transforming growth factor beta 1; Th1, T helper 1 cells; Th2, T helper 2 cells; Th17, T helper 17 cells; Treg, T regulatory cell; TLR4, toll-like receptor 4; anti-dsDNA, anti-double-stranded DNA; ANA, antinuclear antibody; FSP1, fibroblast specific protein; CTGF, connective tissue growth factor; NLRP3, nod-like receptor protein 3; ASC, apoptosis-associated speck-like protein containing CARD; MIP-2, macrophage inflammatory protein-2; MDA, malonyldialdehyde; NO, nitric oxide; GSH, glutathione peroxidase; SOD, superoxide dismutase; CAT, catalase; PCNA, proliferating cell nuclear antigen; α-SMA, α-smooth muscle actin; PI3K/AKT, phosphatidylinositol-3-kinase/protein kinase B; USAG-1, uterine sensitization-associated gene-1; BMP-7, bone morphogenetic protein-7; PGC-1α, peroxisome proliferator-activated receptor γ coactivator 1α; MPC, mitochondrial pyruvate carrier; EMT, epithelial-mesenchymal trans; Smad-2,-3,-7, mothers against decapentaplegic homolog-2,3,7. significance of ↓ and ↑ are at the 0.05 level.

Mechanism of Arss in Kidney {#s4}
===========================

Oxidative Stress Regulation of Artemisinins {#s4_1}
-------------------------------------------

Oxidative stress is an important mediator in the development and progression of CKD and AKI and its complications due to increased production of reactive oxygen species (ROS) and diminished antioxidant capacity ([@B61]). In the condition of a surplus of ROS, ARSs were reported to exhibit an antioxidant effect ([@B31]; [@B83]; [@B44]). In addition, according to the characteristics of ARSs, tumor cells are more vulnerable due to higher levels of iron ([@B59]) and are more susceptible to further ROS insults induced by ARSs ([@B23]; [@B16]). Accordingly, ARSs have the potential to treat kidney cancer, and the emergence of new technologies such as ARS-based smart nanomedicine offers more possibilities ([@B46]).

### In Vitro {#s4_1_1}

Receptor-interacting protein kinase 1 (RIP1) is verified to modulate mitochondrial ROS production *via* excessive generation of mitochondrial superoxide and depletion of GSH ([@B95]). ART was reported to induce ROS production and cell death in human renal carcinoma cells, while pretreatment with RIP1 inhibitor or knockdown of RIP1 reverted ART-induced cytotoxicity ([@B10]).

### In Vivo {#s4_1_2}

Pretreated DHA or ARS could ameliorate oxidative stress in AKI mice by restoring malonyl dialdehyde (MDA), nitric oxide (NO), glutathione peroxidase (GSH), catalase (CAT), and superoxide dismutase (SOD) activity in the kidney ([@B4]; [@B44]). In addition, ARM was shown to reduce the serum H~2~O~2~ level and elevated renal cortical PGC-1α expression, but it did not exert obvious effects on CAT and SOD expression in the renal cortex in DN ([@B24]). In normal rats without oxidative stress, orally taken artemether-lumefantrine (1.14/6.86 mg/kg/d, twice a day) or artesunate-amodiaquine (2.86/8.58 mg/kg/d, twice a day) for 7 d did not apparently alter renal antioxidant status compared with the control. Although there was no significant alteration in kidney, liver, lung, and brain weights, the artesunate-amodiaquine group showed cardiotoxicity (decreased heart weight by 27.2% compared with control) ([@B57]).

To date, ARSs could trigger cell death by inducing oxidative stress, and could also resist oxidation to reduce cell damage. Detailed understanding of the molecular mechanisms and the events by which ARSs regulate oxidative stress to control cellular processes in different cells remain to be explored.

Anti-Inflammation Effect of ARSs {#s4_2}
--------------------------------

Inflammation plays a pivotal role in the pathophysiological processes of kidney diseases and associated with renal injury ([@B17]). The anti-inflammatory effects of ARS have been widely recognized, including repression of nuclear factor-κB (NF-κB), toll-like receptors (TLRs), signal transducer and activator of transcription (STAT), and phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) activity ([@B1]; [@B25]; [@B65]), which are key factors mediating immune-inflammatory response and are associated with kidney disease progression ([@B62]).

### In Vitro {#s4_2_1}

ART ameliorated high glucose-induced injury by suppressing TLR4/NF-κB/nod-like receptor protein 3 (NLRP3) inflammasome pathway in rat glomerular mesangial cell ([@B66]).

### In Vivo {#s4_2_2}

For LN mice, it has been reported that treatment with ARSs could decrease interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) in serum, and blocked intercellular adhesion molecule-1 (ICAM-1), fractalkine, NF-κB signaling pathway in renal ([@B14]; [@B35]; [@B72]; [@B76]; [@B84]; [@B40]). A similar effect was observed in the nephritis and septic AKI models ([@B78]; [@B71]; [@B44]). Also, ARSs were reported to inhibit disease progression *via* downregulating renal monocyte chemoattractant protein 1 (MCP-1) expression in LN, IgAN, and septic AKI models ([@B53]; [@B30]; [@B49]; [@B44]). In addition, ARSs were proved to alleviate the tubule-interstitial inflammation and fibrosis by inhibiting NF‐κB and mothers against decapentaplegic homolog (Smad) signaling pathway in SNx rats, Heymann nephritis rats and UUO models ([@B50]; [@B37]; [@B74]). ARSs were also reported to reduce diabetic kidney damage by inhibiting TLR4, IL-8, and the DNA-binding activity of NF−κB in renal ([@B92]; [@B56]).

These data indicate that ARSs act as anti-inflammatory drugs at multiple components of inflammation signals and have a potential therapeutic effect on disease activity.

Immunoregulatory Effect of ARSs {#s4_3}
-------------------------------

Under physiological conditions, the kidney contributes to immune homeostasis, assist in the removal of metabolic wastes and toxins, and maintain peripheral tolerance. The disruption of immune homeostasis an autoimmune response, such as the occurrence of LN and IgAN, resulting in the loss of renal function ([@B68]). T cells, B cells, and macrophages, as well as cytokines, are involved in immune regulation and are activated to varying degrees depending on disease pattern. The activated pathogenic cells are more likely to lead the breakdown of the peroxide bridge structure of ARS ([@B65]).

### In Vitro {#s4_3_1}

Chemokine ligand 2 (CCL2) and single immunoglobulin IL-1-related receptor (SIGIRR) are involved in the inflammatory pathogenesis of LN, DHA was reported to inhibit CCL2 secretion and increase SIGIRR expression and protect LPS-induced HK-2 inflammation ([@B27]).

### In Vivo {#s4_3_2}

ARS combined with prednisone was reported to increase the sensitivity of glucocorticoid compared to the group administrated glucocorticoid only in LN ([@B79]), which may offer a possibility of alleviating the common side effects of existing glucocorticoids or immunosuppressants. SM934 was shown to protect LN mice by inhibiting both Th1 cells and Th17 cells responses ([@B26]) and reduce the number of activated B cells by inhibiting the expression of TLR7/9 ([@B22]). SIGIRR, as an inhibitor of TLR signal transduction, could be elevated by DHA. This might be a negative immune-modulating way for DHA to slow the progression of LN ([@B27]). In addition, ARS combined with HCQ was shown to improve IgAN rats immunity ([@B41]), possibly *via* inhibiting the differentiation of Th2 and Th17 cells while promoting Th1 and Treg cells differential ([@B5]).

All these studies suggest that ARS family drugs are able to perform immunosuppressive functions primarily through suppressing the activation of pathogenic immune cells and have a regulatory effect on autoimmune diseases.

Other Effects {#s4_4}
-------------

### Anti-Fibrosis {#s4_4_1}

Myofibroblasts can be differentiated by the epithelial-mesenchymal transformation (EMT) process, and are primarily responsible for excessive extracellular matrix production. TGF-β1, smooth muscle actin (α-SMA) and connective tissue growth factor (CTGF), metalloprotease (MMP), bone morphogenetic protein (BMP) are all considered to be major regulators of EMT and renal fibrosis ([@B43]). For UUO, both *in vitro* and *in vivo* study showed anti-fibrosis effect of ARSs related to the inhibition of EMT, fibroblast proliferation, and collagen synthesis ([@B89]). And upregulating BMP-7 and downregulating BMP antagonist-uterine sensitization-associated gene-1 (USAG-1) ([@B8]), or mitigating CTGF, α-SMA ([@B52]), or PI3K/AKT pathway ([@B91]) are all possible mechanisms.

### Anti-Proliferation {#s4_4_2}

Glomerular mesangial cell proliferation is a common pathological change of glomerular disease, effective control of mesangial cell proliferation is of great clinical significance. ARSs were reported to exert an inhibitory effect on the proliferation of rat mesangial cells ([@B47]; [@B48]), possibly by inducing apoptosis and downregulating inflammatory cytokines TNF-α and IL-6 ([@B73]) or enhance caspase-3 activity ([@B77]). Our team recently demonstrated that DHA could inhibit the proliferation of aIgA1-induced human mesangial cells through the mTOR signaling pathway *in vitro* ([@B81]). In addition, ARSs were found to inhibit renal carcinoma cell proliferation by inhibiting the expression of fascin ([@B90]), meanwhile inhibiting colony formation, migration, invasion, and tumorigenesis ([@B85]).

### Regulate Glomerular Filtration {#s4_4_3}

Glomerular permeability is regulated by the glomerular filtration barrier (GFB), which composed of glomerular endothelium, the glomerular basement membrane, and the podocyte layer. The dysfunction of intercellular adhesion and connection will result in the loss of the structural and functional integrity of GFB and the occurrence of proteinuria ([@B51]). ART was proved to reduce glomerular permeability and improve proteinuria in LN mice by inhibiting vascular endothelial growth factor (VEGF) ([@B29]). Studies also showed that DHA ameliorated the hyperpermeability of GFB by inhibiting TNF-α and maintaining occludin expression ([@B12]) or elevation of vascular endothelial (VE)-cadherin expression in endothelial cells ([@B38]). In addition, ARS was observed to attenuate podocyte effacement and fusion *via* nephrin and podocin regulation in adriamycin-induced nephropathy ([@B80]), and reduce the shedding of podocyte and excretion of nephrin and podocin in Heymann nephritis ([@B42]).

### Anti-Virus {#s4_4_4}

ARS was shown to be effective in inhibiting polyomavirus BK replication in primary human kidney cells ([@B64]).

### Renal-Protective. {#s4_4_5}

ART was reported to ameliorate proteinuria and suppress the progression of NS ([@B58]). Studies also showed that ARS could relieve renal lesions in DN rats, through inhibiting platelet-derived growth factor-B (PDGF-B) expression ([@B86]), metalloproteinase tissue inhibitor-2 (TIMP-2) ([@B87]), spatiotemporal dynamics activation of protein kinase c (PKC) ([@B88]) and its downstream c-fos and c-jun ([@B93]), and their heterodimer activator protein (AP-1) ([@B94]). The results from the high-throughput sequence from DN rats treated with ARS may identifying promising targets for future treatment ([@B82]). In addition, kidney function was found to be improved in cases of malarial nephropathy after treatment with ARSs ([@B18]; [@B6]; [@B20]).

Interaction, Safety, and Side Effects {#s5}
=====================================

The toxicity of ARSs in cell culture, animals (mice, rats, rabbits, dogs, monkeys), and human clinical trials were well described ([@B15]). Large clinical studies and meta-analyses did not show serious side effects, despite mild and self-limited effects including mild nausea, vomiting, and diarrhea ([@B54]). Individual patients may appear transient transaminase elevated and mild rash. Non-hematological side effects include mild hepatitis, neurological, renal, cutaneous, and cardiac manifestations were uncommon ([@B60]). Rare severe adverse events include prolongation of the QTc interval and cardiac arrhythmias ([@B28]).

In addition, animal studies showed that artesunate can reduce glomerular filtration rate, increase renal blood flow, and has certain organ toxicity ([@B7]; [@B57]), while in a clinical study, liver function, kidney function, and routine blood tests remained normal in most patients treated with artesunate ([@B70]). A systematic review and meta-analysis showed that the use of ARS-based combination therapy in adults, children, and pregnant women in the 2nd or 3rd trimester was relatively safe ([@B32]). The drug interactions of ARSs are relatively unknown, more rigorous and comprehensive studies of interaction mechanisms are needed, as well as monitoring the safety of ARSs, especially concerning the genotoxicity and embryotoxicity ([@B2]).

Conclusion and Future Directions {#s6}
================================

Much knowledge has been gained about the antimalarial drugs in recent years, and more attention has been paid to ARSs application for renal damages. Many years of laboratory applications and research proved that ARSs have excellent anti-inflammatory and immunoregulatory functions. It is also a good regulator of the balance between oxidation and oxidation resistance. The regulation of the glomerular barrier highlights a unique aspect of the use of ARSs in kidney disease.

Despite accumulating evidence on the use of ARSs, the literature on its potential as a treatment for renal disease is still insufficient due to the lack of randomized controlled clinical trials. The additive effects of ARSs in combined administration with immunosuppressants and the structure-activity relationship need to be further clarified. Investigation of the improved properties of ARSs analogs also facilitates the discovery of novel drug targets for kidney disease ([@B63]; [@B96]; [@B13]).
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